Arrowhead Pharmaceuticals, Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $11.52B |
| Revenue | $622M |
| Net Income | $-301M |
| Total Assets | $2.27B |
| Net Assets | $614M |
| Employees | 711 |
| Value | |
| P/B | 18.77x |
| P/S | 18.52x |
| FCF Yield | -0.44% |
| Profitability | |
| ROE | -49.01% |
| ROA | -13.27% |
| Op. Margin | -35.67% |
| Revenue Growth | -86.41% |
| Earnings Growth | -135.83% |
| Financial Health | |
| Debt Ratio | 271.89% |
| Total Debt | $1.37B |
| FCF | $-51M |
| Cash | $189M |
| Current Ratio | 6.23x |
| Performance | |
| 1Y Return | 423.69% |
| 1M Return | 11.78% |
| From 52W High | -3.25% |
| 1Y MDD | -24.64% |
| Trading | |
| Volume | 1,746,171 shares |
| Trading Value | $143M |
| Per Share | |
| EPS | $1.44 |
| BPS | $4.06 |
Company Info
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.